

NOW ENROLLING IN MELANOMA




PHASE 3 (NCT03635983)

PIVOT IO 001: Bempegaldesleukin with nivolumab in patients with unresectable or metastatic melanoma

A randomized, open-label study of bempegaldesleukin (BEMPEG; NKTR-214) plus nivolumab (NIVO) versus NIVO monotherapy in patients with previously untreated, unresectable or metastatic melanoma^{1,2}

ENROLL NOW

Scan here to find out more about this clinical study at ClinicalTrials.gov



PRIMARY ENDPOINTS

- ORR
- PFS
- OS

KEY SECONDARY ENDPOINTS

- CBR, DOR, TTR
- Safety and tolerability

Bempegaldesleukin is an investigational first-in-class CD122-preferential IL-2–pathway agonist³

Nivolumab is a PD-1 blocking antibody⁴

AJCC, American Joint Committee on Cancer; BEMPEG, bempegaldesleukin (NKTR-214); CBR, clinical benefit rate; DOCR, duration of overall complete response; DOR, duration of response; IL-2, interleukin-2; NIVO, nivolumab; ORR, objective response rate; OS, overall survival; PD-1, programmed death-1; PD-L1, programmed death-ligand 1; PFS, progression-free survival; R, randomized; TTR, time to treatment response.

1. [ClinicalTrials.gov. NCT03635983. https://clinicaltrials.gov/ct2/show/NCT03635983](https://clinicaltrials.gov/ct2/show/NCT03635983). Accessed September 3, 2020. 2. Khushalani NI, *et al*. Presented at: ASCO; May 31–June 4, 2019; Chicago, IL. 3. Charych DH, *et al*. *Clin Cancer Res* 2016;22:680–690. 4. Opdivo (nivolumab) Prescribing Information (Princeton, NJ: Bristol Myers Squibb; revised: June 2020).


ACTIVE CLINICAL TRIALS WITH BEMPEGALDESLEUKIN AND NIVOLUMAB

NEKTAR

Bristol Myers Squibb™

Bempegaldesleukin (BEMPEG; NKTR-214) in combination with nivolumab (NIVO) leverage two immuno-oncology pathways with the aim of addressing the unmet needs of patients living with cancer

FIND OUT MORE
Scan here to discover more about BEMPEG at Nektar.com



BEMPEG, bempegaldesleukin (NKTR-214); NIVO, nivolumab.

FOR EDUCATIONAL PURPOSES ONLY.

This compound and the combination of agents and their uses have not been approved.

Nektar Therapeutics, 455 Mission Bay Boulevard, South San Francisco, California 94158. Copyright Nektar Therapeutics © 2020. All rights reserved.